top of page

Zantac (Ranitidine) Antacid Drug

Bronstein, Gewirtz & Grossman, LLC Alerts Consumers of Zantac Lawsuit

Have you or a loved one taken Zantac and been diagnosed with Cancer? The Zantac lawsuit claims that Zantac can be contaminated with the cancer-causing substance N-nitrosodimethylamine (NDMA). 


If you or a loved one took Zantac and have been diagnosed with any of these cancers, contact us now!

  • Stomach

  • Small intestine

  • Colorectal

  • Esophageal

  • Liver

  • Prostate

  • Pancreatic

  • Leukemia

  • Non-Hodgkins Lymphoma

  • Multiple Myeloma

  • Bladder

  • Kidney

  • Thyroid

  • Breast

  • Testicular


On September 13, 2019, the U.S. Food and Drug Administration (“the FDA”) announced the risk of cancer from Zantac from a chemical contamination. The FDA described how the medications containing ranitidine, including Zantac (ranitidine), contains trace amounts of N-nitrosodimethylamine (NDMA) and that testing has confirmed NDMA to be a potent carcinogen. The FDA continued to state that Zantac has been found to contain these carcinogenic chemicals at 26,000 times the FDA approved.


Since this contamination was first discovered, there have been several Zantac recalls. On September 23, 2019, Sandoz issued the first recall, followed by several generic Zantac makers that supply for Walgreens, Walmart, Rite Aid and CVS. Sanofi, makers of the brand name Zantac issued a recall on October 18, 2019.


The FDA advised the public that it is okay to continue to take over the counter Zantac and other ranitidine medications, and anyone taking prescription Zantac should consult with their physicians if an alternative treatment is available.

Bronstein Gewirtz And Grossman is working tirelessly to alert consumers and to help consumers find out their rights. If you or a loved one have taken Zantac at any time between January 1, 2010 to present and have been diagnosed with Cancer, then you may be eligible for compensation. Know your rights! Complete the form below.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.


Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein 
212-697-6484 |

Know your rights! Complete the form below to find out more.

Anchor 1
bottom of page